LeonaBio, Inc. Common Stock — informes financieros trimestrales (NASDAQ:LONA)

Ver el calendario completo

Financials

Visión general Informes Estadísticas

Trimestre Año

Market Capitalization 37.39 M
Employee 19
Founded 2011
CEO N/A
Website www.leonabio.com
Headquarter Washington, United States
FIGI BBG00C77LX40
Industry Biotecnología

Ingresos totales

Beneficio neto

Beneficio básico por acción

Deuda total

Flujo de caja libre

Efectivo y equivalentes

37.39 M Capitalización de mercado

LeonaBio Inc

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021. The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors. Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer.